Role of PI3 kinase/AKT2 signaling in ovarian oncogenesis

PI3激酶/AKT2信号在卵巢肿瘤发生中的作用

基本信息

  • 批准号:
    6230163
  • 负责人:
  • 金额:
    $ 5.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-09-30 至 2004-09-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: (Applicant's Description) AKT2 is a member of the Akt/protein kinase B family and is activated in response to phosphatidylinositol 3-kinase (PI 3-K)-mediated signals triggered at the cell membrane by growth factors. Amplification and/or overexpression of the AKT2 oncogene are associated with the development of human ovarian carcinomas. Therefore, understanding the role of AKT2 and PI 3-K-mediated signals in the growth regulation of human ovarian surface epithelial (HOSE) cells will contribute to a better understanding of the molecular mechanisms underlying ovarian oncogenesis, which is the broad, long-term objective of this project. The specific aims are: (1) Determine the involvement of AKT2, the related AKT1, and PI 3-K in human ovarian cancer. Examine the expression/kinase activity of AKT2, AKT1, and the catalytic subunit of PI 3-K (p110 alpha) in ovarian carcinoma specimens, and their expression in premalignant lesions in women predisposed to ovarian cancer. Correlate these laboratory findings with various clinicopathologic parameters to determine their clinical relevance. (2) Characterize the role of AKT2 in the regulation of physiological and neoplastic growth of HOSE cells in vitro. Evaluate the effect of the expression and/or activity of AKT2 on growth rate, cell cycle progression, and the induction of apoptosis. Using cDNA expression arrays, identify groups of genes associated with ovarian oncogenesis, whose expression is regulated in response to AKT2 expression/activity. (3) Determine the role of AKT2 in invasion and metastasis of HOSE cells and ovarian cancer cells. Using conditional retroviral expression constructs, investigate the potential involvement of AKT2 expression/activity in cell survival and the development of more invasive or metastatic phenotypes. (4) Identify modulators and substrates of AKT2. Using the yeast two-hybrid system and ovarian cancer-specific phage cDNA expression libraries, identify proteins that interact with AKT2 in the transduction of mitogenic signals in ovarian cancer cells, and determine the physiological significance of these interactions in HOSE cells. Overall, the studies proposed here will provide important new insights regarding the mechanisms by which AKT2 and PI 3-K-mediated signals contribute to ovarian oncogenesis, and may create potential avenues for therapeutic intervention.
描述:AKT2是Akt/蛋白激酶B家族的成员,在响应生长因子在细胞膜上触发的磷脂酰肌醇3-激酶(PI 3-K)介导的信号时被激活。AKT2癌基因的扩增和/或过表达与人类卵巢癌的发展有关。因此,了解AKT2和PI 3- k介导的信号在人卵巢表面上皮细胞(HOSE)生长调节中的作用,将有助于更好地了解卵巢肿瘤发生的分子机制,这是本项目广泛而长期的目标。具体目的是:(1)确定AKT2、相关的AKT1和PI 3-K在人卵巢癌中的作用。检测卵巢癌标本中AKT2、AKT1和pi3 - k催化亚基(p110 α)的表达/激酶活性,以及它们在卵巢癌易感女性癌前病变中的表达。将这些实验室结果与各种临床病理参数相关联,以确定其临床相关性。(2)表征AKT2在体外调控HOSE细胞生理和肿瘤生长中的作用。评估AKT2的表达和/或活性对生长速率、细胞周期进程和诱导凋亡的影响。利用cDNA表达阵列,鉴定与卵巢肿瘤发生相关的基因群,其表达受AKT2表达/活性的调控。(3)确定AKT2在HOSE细胞和卵巢癌细胞侵袭转移中的作用。使用条件逆转录病毒表达构建,研究AKT2表达/活性在细胞存活和更具侵袭性或转移性表型发展中的潜在参与。(4)鉴定AKT2的调制器和底物。利用酵母双杂交系统和卵巢癌特异性噬菌体cDNA表达文库,鉴定卵巢癌细胞中与AKT2相互作用的有丝分裂信号转导蛋白,并确定这些相互作用在HOSE细胞中的生理意义。总的来说,本文提出的研究将为AKT2和PI 3- k介导的信号促进卵巢肿瘤发生的机制提供重要的新见解,并可能为治疗干预创造潜在的途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(8)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph R. Testa其他文献

Amplification of the c-myc oncogene is associated with an abnormally banded region on chromosome 8 or double minute chromosomes in two HL-60 human leukemia sublines.
c-myc 癌基因的扩增与两个 HL-60 人类白血病亚系中 8 号染色体或双小染色体上的异常带状区域有关。
  • DOI:
  • 发表时间:
    1987
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Shinichi Misawa;Stephen P. Staal;Joseph R. Testa
  • 通讯作者:
    Joseph R. Testa
Minimally differentiated acute nonlymphocytic leukemia: a distinct entity.
微分化急性非淋巴细胞白血病:一个独特的实体。
  • DOI:
  • 发表时间:
    1987
  • 期刊:
  • 影响因子:
    20.3
  • 作者:
    EJ Lee;A. Pollak;Richard D. Leavitt;Joseph R. Testa;Charles A. Schiffer
  • 通讯作者:
    Charles A. Schiffer
Novel human and mouse annexin A10 are linked to the genome duplications during early chordate evolution.
新型人类和小鼠膜联蛋白 A10 与早期脊索动物进化过程中的基因组复制有关。
  • DOI:
  • 发表时间:
    1999
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    R. O. Morgan;N. Jenkins;D. Gilbert;N. Copeland;B. Balsara;Joseph R. Testa;M. Fernández
  • 通讯作者:
    M. Fernández
MP40-06 MOST CYTOGENETICALLY PROVEN RENAL ONCOCYTOMAS AND CHROMOPHOBE CARCINOMAS CAN BE DIFFERENTIATED BY ROUTINE H&E AND CYTOKERATIN 7 STAINS ALONE
  • DOI:
    10.1016/j.juro.2014.02.1341
  • 发表时间:
    2014-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Reza Mehrazin;Essel Dulaimi;Hussam Nash;Alexander Kutikov;Jeffrey J. Tomaszewski;Jianming Pei;Marc C. Smaldone;Philip Abbosh;Timothy Ito;Joseph R. Testa;Tahseen Al-Saleem;Robert G. Uzzo
  • 通讯作者:
    Robert G. Uzzo
Unusual karyotypic changes and B cell involvement in a case of lymph node blast crisis of chronic myelogenous leukemia.
慢性粒细胞白血病淋巴结母细胞危象一例异常核型变化和 B 细胞受累。
  • DOI:
  • 发表时间:
    1984
  • 期刊:
  • 影响因子:
    20.3
  • 作者:
    DE Hogge;Shinichi Misawa;Joseph R. Testa;Richard D. Leavitt;A. Pollak;Charles A. Schiffer
  • 通讯作者:
    Charles A. Schiffer

Joseph R. Testa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph R. Testa', 18)}}的其他基金

Role of the Parkinson's susceptibility gene LRRK2 in NFAT-mediated malignant mesothelioma tumorigenesis
帕金森病易感基因 LRRK2 在 NFAT 介导的恶性间皮瘤肿瘤发生中的作用
  • 批准号:
    10653572
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
AKT AND TUMOR SUPPRESSOR PATHWAYS IN MESOTHELIOMA
间皮瘤中的 AKT 和肿瘤抑制途径
  • 批准号:
    7035624
  • 财政年份:
    2005
  • 资助金额:
    $ 5.55万
  • 项目类别:
AKT as a Biomarker of Ovarian Cancer Progression and a Target for Therapeutic Int
AKT 作为卵巢癌进展的生物标志物和治疗整合的靶点
  • 批准号:
    6958701
  • 财政年份:
    2004
  • 资助金额:
    $ 5.55万
  • 项目类别:
CORE--RESEARCH CYTOGENETICS
核心--研究细胞遗传学
  • 批准号:
    6652221
  • 财政年份:
    2002
  • 资助金额:
    $ 5.55万
  • 项目类别:
Role of PI3 kinase/AKT2 signaling in ovarian oncogenesis
PI3激酶/AKT2信号在卵巢肿瘤发生中的作用
  • 批准号:
    6667423
  • 财政年份:
    2002
  • 资助金额:
    $ 5.55万
  • 项目类别:
Role of PI3 kinase/AKT2 signaling in ovarian oncogenesis
PI3激酶/AKT2信号在卵巢肿瘤发生中的作用
  • 批准号:
    6504970
  • 财政年份:
    2001
  • 资助金额:
    $ 5.55万
  • 项目类别:
CORE--RESEARCH CYTOGENETICS
核心--研究细胞遗传学
  • 批准号:
    6485987
  • 财政年份:
    2001
  • 资助金额:
    $ 5.55万
  • 项目类别:
Role of PI3 kinase/AKT2 signaling in ovarian oncogenesis
PI3激酶/AKT2信号在卵巢肿瘤发生中的作用
  • 批准号:
    6352800
  • 财政年份:
    2000
  • 资助金额:
    $ 5.55万
  • 项目类别:
Role of PI3 kinase/AKT2 signaling in ovarian oncogenesis
PI3激酶/AKT2信号在卵巢肿瘤发生中的作用
  • 批准号:
    6323313
  • 财政年份:
    1999
  • 资助金额:
    $ 5.55万
  • 项目类别:
Basis for Lymphomagenesis in Akt2 Transgenic Mice
Akt2 转基因小鼠淋巴瘤发生的基础
  • 批准号:
    7743099
  • 财政年份:
    1998
  • 资助金额:
    $ 5.55万
  • 项目类别:

相似海外基金

Dissecting the roles of iron and hemojuvelin in hepatocellular carcinoma
剖析铁和血幼素在肝细胞癌中的作用
  • 批准号:
    478251
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
    Operating Grants
Combination therapy for renal cell carcinoma using oncolytic virus G47d
使用溶瘤病毒 G47d 联合治疗肾细胞癌
  • 批准号:
    23K08752
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Preoperative molecular diagnosis with novel follicular thyroid carcinoma-specific markers using cytology and blood samples
使用细胞学和血液样本进行新型滤泡性甲状腺癌特异性标记物的术前分子诊断
  • 批准号:
    23K08060
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Impact of sarcopenia and creation of novel therapeutic targets by immunotherapeutic resistance mechanisms in hepatocellular carcinoma
肌少症的影响以及通过免疫治疗耐药机制创建新的治疗靶点对肝细胞癌的影响
  • 批准号:
    23K08106
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of transcatheter arterial embolization for controlling hypoxia in hepatocellular carcinoma
经导管动脉栓塞控制肝细胞癌缺氧的研究进展
  • 批准号:
    23K07075
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of the antioxidant function of xCT in lymphatic endothelial cells and its significance in oral squamous cell carcinoma.
淋巴管内皮细胞xCT抗氧化功能分析及其在口腔鳞癌中的意义
  • 批准号:
    23K16139
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Search for therapeutic target molecules based on temporal hierarchical analysis of Oral squamous cell carcinoma and functional RNA molecules
基于口腔鳞状细胞癌和功能RNA分子的时间层次分析寻找治疗靶分子
  • 批准号:
    23K16142
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
An actionable secretory program that drives tumor progression in a genetically defined subset of lung squamous carcinoma
一种可操作的分泌程序,可驱动基因定义的肺鳞癌亚群中的肿瘤进展
  • 批准号:
    10646979
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
Development of miR-27a* for the Treatment of Head and Neck Squamous Cell Carcinoma
开发 miR-27a* 用于治疗头颈鳞状细胞癌
  • 批准号:
    10752726
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
Investigating a new vulnerability in oral squamous cell carcinoma
研究口腔鳞状细胞癌的新脆弱性
  • 批准号:
    10714352
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了